



August 5, 2013

Gene Techno Science Co.,Ltd.
Code: 4584 (TSE Mothers)
President
Masanari Kawaminami

Notice of Establishment of Capital and Business Alliance, and Issuance of New Shares Through a Private Placement

Gene Techno Science Co.,Ltd. announces that its Board of Directors approved a resolution on August 5, 2013 to establish a capital and business alliance with Itochu Chemical Frontier Corporation and to issue new shares through a private placement to this company.

1. Purpose and reason of capital and business alliance

This business alliance is for the joint development of the first biosimilar. The role of Itochu Chemical Frontier in this business alliance is to utilize its business networks in Japan and overseas as much as possible in order to locate the most suitable outsourcing partners for the development of biosimilars as well as to locate pharmaceutical companies to sell the pharmaceutical product. The role of Gene Techno Science is to oversee these outsourcing partners, following their evaluation and selection, and perform development steps up to the non-clinical trial stage efficiently and with no problems.

Itochu Chemical Frontier is a wholly owned subsidiary of ITOCHU Corporation (Code: 8001, TSE 1st Section), and performs the key role of helping maintain a stable supply of high-quality pharmaceutical ingredients and finished pharmaceuticals for Japanese pharmaceutical companies and other customers by purchasing these items from manufacturers around the world. Providing a reliable supply of generic drugs is becoming increasingly important due to the growth of the market for these drugs. Itochu Chemical Frontier inspects the facilities of overseas manufacturers, performs quality tests and quality assurance at its own testing laboratory, and has expertise involving the drug approval application process. All of these activities create a sound base for the consistent supply of pharmaceuticals. In addition, Itochu Chemical Frontier was first in Japan to start importing generic anticancer drugs in response to the substantial growth in demand for these drugs in recent years. These imports are making a contribution to increasing the use of generic drugs to fight cancer.

Due to the belief that combining the resources of Gene Techno Science and Itochu Chemical Frontier will speed up the development of biosimilars, Gene Techno Science has decided to establish this business alliance for the development of biosimilars and to establish this capital alliance.

2. Profile of Itochu Chemical Frontier Corporation

(1) Name	ITOCHU CHEMICAL FRONTIER Corporation
(2) Address	2-5-1, Kita-Aoyama, Minato-ku, Tokyo
(3) Representative	Shinichiro Makida, President & Chief Executive Officer
(4) Main business	Imports, exports and sales in Japan of pharmaceutical-related chemicals and fine chemicals and other activities
(5) Capital	1,100,000,000 yen
(6) Established	September 6, 1971
(7) Major shareholders and shareholding ratio	ITOCHU Corporation (Code: 8001, Tokyo Stock Exchange 1st Section) 100.00%
(8) URL	http://www.itcchem.co.jp

3. Overview of fund procurement

(1) Payment date	August 22, 2013
(2) Number of shares to be newly issued	Common stock of 41,900 shares
(3) Issue price	4,816 yen
(4) Amount of funds to be raised	201,790,400 yen
(5) Use of proceeds	Introduction of producer cells, studies concerning production methods and quality, and non-clinical trials for the development of the first biosimilar

Media Contact

Eisaku Nakamura
Business Development Dept.
Tel: (81)-3-3517-1353
E-mail: info@g-gts.com